Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study

Ayaz, Nuray Aktay; Karadağ, Şerife Gül; Koç, Rahime; Demirkan, Fatma Gül; Çakmak, Figen; Sönmez, Hafize Emine

doi:10.1007/s00296-020-04596-3

Cited by 8 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, fatigue and physical function significantly improved in TCZ treated GCA-patients compared with those receiving steroids only 183. In JIA, patients switching route of administration from intravenous to SC reported satisfaction in terms of life quality, school success and reduced school absenteeism 184. On the other side, in patients with RA, TCZ discontinuation was predicted by low initial CRP levels, high scale on the Health Assessment Questionnaire (HAQ), high fatigue and pain, smoking and exposure to bDMARD before TCZ therapy 185 186.…”

Section: Resultsmentioning

confidence: 95%

“… 183 In JIA, patients switching route of administration from intravenous to SC reported satisfaction in terms of life quality, school success and reduced school absenteeism. 184 On the other side, in patients with RA, TCZ discontinuation was predicted by low initial CRP levels, high scale on the Health Assessment Questionnaire (HAQ), high fatigue and pain, smoking and exposure to bDMARD before TCZ therapy. 185 186 Finally, five studies addressing the cost-effectiveness related to the usage of TCZ and SAR were included.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

et al. 2022

View full text Add to dashboard Cite

ObjectivesInforming an international task force updating the consensus statement on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) selectively targeting interleukin-6 (IL-6) pathway in the context of immune-mediated inflammatory diseases.MethodsA systematic literature research of all publications on IL-6 axis inhibition with bDMARDs published between January 2012 and December 2020 was performed using MEDLINE, EMBASE and Cochrane CENTRAL databases. Efficacy and safety outcomes were assessed in clinical trials including their long-term extensions and observational studies. Meeting abstracts from ACR, EULAR conferences and results on clinicaltrials.gov were taken into consideration.Results187 articles fulfilled the inclusion criteria. Evidence for positive effect of IL-6 inhibition was available in various inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still’s disease, cytokine release syndrome due to chimeric antigen receptor T cell therapy and systemic sclerosis-associated interstitial lung disease. Newcomers like satralizumab and anti-IL-6 ligand antibody siltuximab have expanded therapeutic approaches for Castleman’s disease and neuromyelitis optica, respectively. IL-6 inhibition did not provide therapeutic benefits in psoriatic arthritis, ankylosing spondylitis and certain connective tissue diseases. In COVID-19, tocilizumab (TCZ) has proven to be therapeutic in advanced disease. Safety outcomes did not differ from other bDMARDs, except higher risks of diverticulitis and lower gastrointestinal perforations. Inconsistent results were observed in several studies investigating the risk for infections when comparing TCZ to TNF-inhibitors.ConclusionIL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In pediatric and adult rheumatology, many patients receiving IV tocilizumab were switched to the SQ form as the supply of IV tocilizumab was consumed for treatment of severe COVID-19. This switch to SQ tocilizumab resulted in patient/parent anxiety of the risk of disease flare or worsening disease activity even though switching to subcutaneous route has been found to be effective alternative for children with juvenile idiopathic arthritis 83 . Other drugs, e.g.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 on Pediatric Immunocompromised Patients

Connelly

Chong

Esbenshade

et al. 2021

Pediatric Clinics of North America

View full text Add to dashboard Cite

Synopsis: Although living with the threat of severe infection is a constant worry for many pediatric immunocompromised patients, the pandemic begotten by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) created new fears and challenges for families and health care providers. As people around the world through government directive or independent choice moved into protective isolation, immunosuppressed children who routinely require medical management were challenged with necessary public ventures to health care facilities. Medical centers adapted by developing new approaches to care for immunocompromised children such as expanding telemedicine services and conversion to at home immune therapies to reduce infectious exposure. Testing for SARS-CoV-2 of asymptomatic patients prior to medical therapies became routine in most modern health care units and development of highly sensitive assays was critical to avoid patient and staff exposure as well as initiation of new immunosuppressive treatment in positive patients. As the prevalence of coronavirus disease (COVID-19) amplified and infected immunocompromised patients became more common, questions quickly arose including how aggressively to treat the infection with most agents still in clinical trials. Additionally how should chronic immunosuppressant drugs that may interfere with the ability to clear the virus be adjusted? Finally, what if the infection leads to excessive immune responses or flares of the underlying disorder? In this review, we explore the impact of the COVID-19 pandemic on immunocompromised children during the first year, summarizing what is known and yet to be discovered, approaches to testing and treatment of SARS-CoV-2, considerations in management of underlying immune suppressive medications, outcomes published to date, and strategies for vaccinating this unique population.

show abstract

“…Based on the patient satisfaction questionnaire, 8 out of the 9 patients reported satisfaction with SQ administration, highlighting improvements in quality of life, school performance, and reduced school absenteeism. 16 In addition to rheumatology, other chronic diseases such as inflammatory bowel disease, patient satisfaction with the change in route of administration has been evaluated, including during the COVID-19 pandemic, and has shown a preference for the SQ route. 28 In studies of patients with lymphoma, that the RASQ has been used to assess patient preference and satisfaction with SQ versus IV administration of rituximab, it has been observed that patient satisfaction was higher with SQ administration.…”

Section: Discussionmentioning

confidence: 99%

“…Few studies have assessed patient´s satisfaction when transitioning from IV to SQ treatment in rheumatoid arthritis (RA) patients, and the available results are contradictory, depending on patient characteristics mainly in favor of the SQ route. [12][13][14][15][16] In this context, BEST-LUPUS (BElimumab Switching Therapy in patients with well controlled systemic LUPUS erythematosus) aimed to explore the effectiveness and patient satisfaction of switching from IV to SQ BEL administration in patients with SLE. By assessing disease activity, treatment response, and patient-reported outcomes (PROs), we aimed to provide valuable insights into clinical outcomes and patient experiences with the SQ formulation.…”

Section: Introductionmentioning

confidence: 99%

Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice

Frade-Sosa,

Salman-Monte,

Narváez

et al. 2024

Lupus

View full text Add to dashboard Cite

Background In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction. Methods Observational, multicenter study, conducted in 7 reference centers in Catalonia. We included stable SLE patients (EULAR/ACR 2019) on treatment with SQ BEL and previous use of IV BEL (at least 3 months on IV BEL before switching). Since there are no well-validated tools for SQ BEL treatment satisfaction, we used RASQ-SQ, validated in patients with lymphoma who switched from IV Rituximab to SQ treatment, and modified for BEL treatment. Results Twenty-seven patients were included. The more prevalent clinical manifestations observed were related to the skin and joints and the patients had a mean baseline SLEDAI of 2.96 (SD 2.4) and SLICC score of 0.67 (SD 0.88). The median time from treatment with IV BEL before switching to SQ was 21 months (range). 84% of patients reported confidence in SQ BEL. 85.2% felt that treatment with SQ BEL was convenient or very convenient. 85% felt they had gained time with the change. 89% would recommend the SQ injection to other patients. Disease activity (mean SLEDAI) and remission rates remain stable after switching. No major new adverse effects were reported. Conclusions Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment. A switching SQ strategy is a reasonable alternative for BEL patients.

show abstract

Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study

Cited by 8 publications

References 18 publications

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

Impact of COVID-19 on Pediatric Immunocompromised Patients

Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice

Contact Info

Product

Resources

About